BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 20, 2025
Breaking News: Trump administration impacts
Breaking News: Trump administration impacts
Breaking News: Trump administration impacts
Breaking News: Trump administration impacts
Home
»
Topics
» BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric
RSS
Biogen introduces Avonex in first market
May 24, 1996
ICN will market fluoxetine in Russia, ex-Yugoslavia
May 24, 1996
Fujisawa, Nihon Shokubai claim CCK-B antagonists
May 24, 1996
ADIR claims melatonin receptor ligands for CNS disorders
May 24, 1996
Ultiva okayed for marketing in Germany; U.S. approval recommended by committee
May 24, 1996
Rizatriptan NDA filing expected in mid-1997
May 24, 1996
L-742694: Morpholine-based NK1 antagonist
May 24, 1996
CP-122721 shows potent affinity for NK1 receptors after oral dosing
May 24, 1996
Myotrophin up for advisory committee review
May 17, 1996
Memantine to be tested in AIDS-related dementia, painful peripheral neuropathies
May 17, 1996
Previous
1
2
…
2723
2724
2725
2726
2727
2728
2729
2730
2731
…
2739
2740
Next
RSS